Cerevel blames Covid for delayed neuroscience studies, says president is leaving
Neuroscience biotech Cerevel Therapeutics said data readouts for several clinical trials will come later than originally expected, and also disclosed the upcoming departure of its president, Abraham Ceesay.
The affected trials include a Phase II in focal epilepsy for darigabat, three Phase III trials for tavapadon in Parkinson’s and a Phase IIa of CVL-871 in dementia-related apathy. The epilepsy trial will read out sometime after 2023, the company said. Data had been expected in mid-2023. Another Phase II for darigabat will start next quarter in panic disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.